The company's immunology portfolio, led by Skyrizi and Rinvoq, continues to thrive despite Humira's patent expiration, ...

Abbvie said on Friday it would record a charge of about $3.5 billion related to its experimental schizophrenia drug, ...

AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with ...

The pharmaceutical landscape enters 2025 with a mix of challenges and opportunities, with the potential to shape the future ...

The bevy of changes for the massive California nonprofit is meant to improve operations, and should also give Blue Shield a ...

AbbVie lowered its 2024 adjusted profit forecast on Monday as the drugmaker incurred $1.6 billion in acquisition expenses ...

The drugs are listed in alphabetical order. Adalimumab-Adbm injection: Boehringer Ingelheim Pharmaceuticals discontinued two presentations of Cyltezo, its biosimilar to Humira. The injectable ...

Oakland-based Blue Shield of California on Wednesday announced a new CEO and COO along with a new parent company in a move ...

After years of patent protection, biosimilars for Humira are set to enter the US market in 2023. The arrival of these drugs has been widely anticipated throughout the healthcare industry.

Truist analyst Srikripa Devarakonda lowered the firm’s price target on AbbVie (ABBV) to $211 from $215 and keeps a Buy rating on the shares as ...

Investment analysts at Leerink Partnrs dropped their FY2024 EPS estimates for AbbVie in a research note issued to investors ...